Continuous infusion of dexamethasone aggravates the damage of cartilage via upregulating p-AKT and impairing articular autophagy in experimental OA model

Liang Chen, Zhenhong Ni, Jinfan Zhang, Junlan Huang, Yangli Xie, Bin Zhang, Liang Kuang, Xianding Sun, Dali Zhang, Nan Su, Huabing Qi, Qiaoyan Tan, Jing Yang, Min Kyung Jin, Fengtao Luo, Hangang Chen, Siru Zhou, Xiaolan Du, Junjie Ouyang, Zuqiang Wang, Lin ChenResearch 2020 · DOI

Abstract

Objective: To explore the effect of dexamethasone (Dex) infusion on articular cartilage and the underlying mechanisms in vitro and in vivo.

Methods: Destabilization of medial meniscus (DMM)-induced OA mouse model was used in this study. The mice with Dex treatment were sacrificed and then the knee joint samples were obtained for pathological analysis. Mouse primary chondrocytes were isolated and cultured in the presence or absence of Dex, which were used for calcification analysis and western blot assay.

Results: Dex accelerated the loss of articular cartilage matrix in mice, while it aggravated the damage of cartilage in DMM-induced OA model at the late stage. The calcium content in calcified cartilage layer in the joints from Dex treated OA mice was significantly higher than that from control mice. Dex treatment enhanced mineralization of articular cartilage matrix and leaded to massive apoptosis of chondrocytes in OA model. In addition, Dex caused autophagy of chondrocytes in the early stage, which was decreased at the late stage of Dex treatment. Moreover, we found that the effect of Dex on the mineralization of articular cartilage matrix in mice was related to AKT activation.

Conclusions: Continuous infusion of Dex can enhance the calcification of cartilage via AKT activation and increase chondrocyte apoptosis through inhibiting autophagy, which aggravates the damage of articular cartilage and accelerates the progression of OA in vivo.

Introduction

Osteoarthritis (OA) is a leading cause of disability worldwide, characterized by the progressive breakdown of articular cartilage. Clinicians frequently use corticosteroids like dexamethasone (Dex) to treat inflammatory "flares" due to their potent anti-inflammatory effects. However, the long-term safety of these drugs remains controversial; clinical evidence suggests that prolonged use might actually speed up cartilage loss.

The biological mechanisms behind this damage have remained unclear. This research investigates the specific molecular pathways by which dexamethasone influences cartilage matrix mineralization and cell survival, aiming to clarify the risks associated with prolonged steroid use in joint disease.

Experimental Methodology

The study employed a multi-level experimental approach to observe the effects of Dex on joint health:

  • Animal Model: A "Destabilization of Medial Meniscus" (DMM) mouse model was used to simulate OA. Mice were treated with continuous intraperitoneal injections of Dex (5 mg/kg, three times weekly) for up to 12 weeks.
  • In Vitro Studies: Primary chondrocytes were isolated from mice and cultured to observe the direct effects of Dex on mineralization and protein expression.
  • Advanced Imaging: To measure mineral changes, the team used Scanning Electron Microscopy (SEM) and Energy Dispersive Spectrometer (EDS) detection to map calcium gradients in the cartilage layers.
  • Molecular Signaling: Western blotting and immunohistochemistry were used to track the activation of the AKT pathway (a key regulator of cell growth and metabolism) and LC3 (a marker for autophagy).
  • Human Validation: The researchers also examined cartilage samples from human OA patients who had a history of repeated corticosteroid injections to validate the animal findings.

Key Insights and Results

The Role of AKT Signaling

The study identifies the AKT signaling pathway (specifically p-AKT308) as a primary driver of Dex-induced damage. Dex upregulates p-AKT, which in turn promotes the pathological calcification of the extracellular matrix. Dex treatment led to a nearly 90% increase in p-AKT308 positive cells in the deep layers of cartilage.

Autophagy and Chondrocyte Survival

Dex initially increases autophagy in chondrocytes as a protective stress response. However, this mechanism eventually fails. While LC3-positive cells (markers of autophagy) were high at 4 and 8 weeks, they were almost non-existent by 12 weeks. When autophagy is impaired, the cells can no longer survive the stress and undergo apoptosis (programmed cell death).

Pathological Mineralization

Dex significantly increases calcium content in the calcified cartilage layer (CCL). This hyper-mineralization creates "horizontal clefts" at the junction of calcified and non-calcified cartilage, leading to the structural "peeling" of the joint surface. Calcium levels were abnormally high as early as 4 weeks into Dex treatment.

The Anti-inflammatory Paradox

The paper highlights a critical irony: while Dex successfully reduced synovial inflammation (synovitis), it simultaneously accelerated the structural collapse of the cartilage. By 8 and 12 weeks, Dex-treated mice showed significantly higher OARSI scores (indicating worse damage) and a massive loss of extracellular matrix compared to untreated OA mice.

Limitations and Future Directions

While these findings are significant, the authors acknowledge that the continuous intraperitoneal infusion used in the mouse model may exaggerate the effects seen in clinical settings, where human patients typically receive intermittent local injections.

Future research could investigate whether co-administering AKT inhibitors or autophagy enhancers alongside steroids could preserve the anti-inflammatory benefits while protecting the cartilage structure. Identifying the exact molecular "switch" that turns the initial protective autophagy response into failure remains a key goal for future studies.

Summary updated

Abstract

Abstract Objective To explore the effect of dexamethasone (Dex) infusion on articular cartilage and the underlying mechanisms in vitro and in vivo . Methods Destabilization of medial meniscus (DMM)-induced OA mouse model was used in this study. The mice with Dex treatment were sacrificed and then the knee joint samples were obtained for pathological analysis. Mouse primary chondrocytes were isolated and cultured in the presence or absence of Dex, which were used for calcification analysis and western blot assay. Results Dex accelerated the loss of articular cartilage matrix in mice, while it aggravated the damage of cartilage in DMM-induced OA model at the late stage. The calcium content in calcified cartilage layer in the joints from Dex treated OA mice was significantly higher than that from control mice. Dex treatment enhanced mineralization of articular cartilage matrix and leaded to massive apoptosis of chondrocytes in OA model. In addition, Dex caused autophagy of chondrocytes in the early stage, which was decreased at the late stage of Dex treatment. Moreover, we found that the effect of Dex on the mineralization of articular cartilage matrix in mice was related to AKT activation. Conclusions Continuous infusion of Dex can enhance the calcification of cartilage via AKT activation and increase chondrocyte apoptosis through inhibiting autophagy, which aggravates the damage of articular cartilage and accelerates the progression of OA in vivo.
BibTeX
@inproceedings{chen2020continuous,
  author = {Liang Chen and Zhenhong Ni and Jinfan Zhang and Junlan Huang and Yangli Xie and Bin Zhang and Liang Kuang and Xianding Sun and Dali Zhang and Nan Su and Huabing Qi and Qiaoyan Tan and Jing Yang and Min Kyung Jin and Fengtao Luo and Hangang Chen and Siru Zhou and Xiaolan Du and Junjie Ouyang and Zuqiang Wang and Lin Chen},
  title = {{Continuous infusion of dexamethasone aggravates the damage of cartilage via upregulating p-AKT and impairing articular autophagy in experimental OA model}},
  booktitle = {Research},
  year = {2020},
  doi = {10.21203/rs.3.rs-71569/v1},
}
Figure